BMS Avoids Charge As Prosecution Deal Expires
The U.S. Attorney's Office in New Jersey has dropped a securities fraud charge against Bristol-Myers Squibb Co., saying the drug maker has turned itself around in the past two years....To view the full article, register now.
Already a subscriber? Click here to view full article